Shopping Cart

Your shopping cart is currently empty

Bay 41-4109

Name: Bay 41-4109
Brand: TargetMol
SKU: T10480L
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: Methyl (4R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate, BAY41-4109, (R)-Bay 41-4109) Copy Product Info

🥰Excellent

Synonyms: Methyl (4R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate, BAY41-4109, (R)-Bay 41-4109

Catalog No. T10480L Copy Product Info

🥰Excellent

BAY 41-4109 (Methyl (4R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate) is a potent inhibitor of human hepatitis B virus (HBV)(IC50 : 53 nM).

Cas No. 298708-81-3

Pack Size	Price	USA Stock	Global Stock	Quantity
2 mg	$68	-	In Stock
1 mL x 10 mM (in DMSO)	$29	6-8 weeks	6-8 weeks

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Appearance:Solid

Color:Yellow

Resource Download

COA

Product Introduction

Bioactivity

Description	BAY 41-4109 (Methyl (4R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate) is a potent inhibitor of human hepatitis B virus (HBV)(IC50 : 53 nM).
Targets & IC50	HepG2.2.15 cells:7 μM (cc50), HBV:50 nM
In vitro	Method: In HepG2.2.15 cells, the inhibitory effects of BAY 41-4109 on HBV DNA release and cytoplasmic HBcAg levels were measured, and the half-maximal inhibitory concentrations (IC50) were calculated. The dose-response relationship for both parameters and the association between the anti-HBV mechanism and HBcAg inhibition were evaluated. Result: The IC50 values of BAY 41-4109 for inhibiting HBV DNA release and cytoplasmic HBcAg levels were 32.6 nM and 132 nM, respectively, indicating a stronger inhibitory effect on HBV DNA. Both HBV DNA and HBcAg were inhibited in a dose-dependent manner, suggesting that the anti-HBV mechanism is associated with and dependent on the rate of HBcAg inhibition [1]. Method: Human HepG2.2.15 cells were treated with BAY 41-4109 for 8 days. Inhibition of HBV DNA was detected using dot-blot hybridization and quantified by LumiImager, and cytotoxicity (CC50) was also determined. Result: The IC50 of BAY 41-4109 for inhibiting HBV replication was approximately 53 nM, and the CC50 in HepG2.2.15 cells was approximately 7 μM [3]. Method: HepAD38 cells were treated with BAY 41-4109 (2 μM) for 6 days. Supernatant HBV DNA was quantified by qPCR, and HBeAg and HBsAg levels were measured by ELISA. Result: Following BAY 41-4109 treatment, HBV DNA inhibition exceeded 95% (residual DNA was 4.9% ± 2.8% of the DMSO control), and HBeAg secretion was significantly reduced (to 31.8% ± 3.8% of the control), with an EC50 of 0.05 ± 0.003 μM [4].
In vivo	Method: In a transgenic mouse model, the effect of BAY 41-4109 treatment on HBV replication was evaluated. Result: BAY 41-4109 inhibited HBV virion production at nanomolar concentrations in an animal model. Its mechanism of action involves targeting the viral capsid protein, leading to the formation of aberrant capsids and subsequently suppressing viral replication [2]. Method: HBV transgenic mice (Tg [HBV1.3 fsX-3'5']) were orally administered BAY 41-4109 (3-30 mg/kg) twice daily (b.i.d.) or three times daily (t.i.d.) for 28 days. Hepatic HBV DNA was detected by dot-blot hybridization, plasma HBV DNA was quantified by real-time qPCR, and HBcAg expression in liver tissues was examined by immunohistochemistry. Result: BAY 41-4109 reduced hepatic and plasma HBV DNA levels in a dose-dependent manner, with significant effects observed at doses of 30 mg/kg and 15 mg/kg (P < 0.05). Unlike 3TC, BAY 41-4109 markedly reduced HBcAg in the cytoplasm of hepatocytes, suggesting a mechanism of action distinct from that of nucleoside analogs. Pharmacokinetic analysis revealed an oral bioavailability of 30% in mice and a half-life of approximately 2 hours [3].
Synonyms	Methyl (4R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoropyridin-2-yl)-6-methyl-1,4-dihydropyrimidine-5-carboxylate, BAY41-4109, (R)-Bay 41-4109

Chemical Properties

Molecular Weight	395.76
Formula	C₁₈H₁₃ClF₃N₃O₂
Cas No.	298708-81-3
Smiles	C(OC)(=O)C=1[C@@H](NC(=NC1C)C2=C(F)C=C(F)C=N2)C3=C(Cl)C=C(F)C=C3
Relative Density.	1.46 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 80 mg/mL (202.14 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (8.34 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.5268 mL	12.6339 mL	25.2678 mL	126.3392 mL
5 mM	0.5054 mL	2.5268 mL	5.0536 mL	25.2678 mL
10 mM	0.2527 mL	1.2634 mL	2.5268 mL	12.6339 mL
20 mM	0.1263 mL	0.6317 mL	1.2634 mL	6.3170 mL
50 mM	0.0505 mL	0.2527 mL	0.5054 mL	2.5268 mL
100 mM	0.0253 mL	0.1263 mL	0.2527 mL	1.2634 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc